Biotech giant Gilead Sciences Inc. and its Kite Pharma Inc. subsidiary in Santa Monica are buying Cell Design Labs Inc. for up to $567 million as the battle to develop cancer-targeting cell therapies heats up.
Gilead of Foster City, which bought Kite Pharma in August for $12 billion, said Thursday the deal to acquire the Emeryville-based lab would close shortly.
“The transaction will build on Gilead’s recent acquisition of Kita Pharma Inc. and has the potential to help the Gilead and Kite organizations accelerate the development of next generation cellular therapy candidates,” the companies said in a joint news release.
The transaction includes an up-front payment of $175 million, plus added payments of $322 million upon meeting certain milestones. About 12.2 percent of shares in Cell Design held by Kite are included as part of the deal.
Among Cell Design Labs’ chief investors and board members is Los Angeles biotech maverick Dr. Arie Belldegrun, founder of Kite Pharma and now a major advisor.
The acquisition strengthens Gilead’s position as developer of chimeric antigen receptor T-cell therapy (CART-T) drugs, a new class of treatments that transform a patient’s immune cells to target cancer.
In October, Kite won federal approval for a Yescarta CAR-T treatment for adults with non-Hodgkin’s lymphoma. In August, competitor Novartis AG won federal approval for the first cell-based cancer treatment in the U.S. for acute leukemia.
Cell Design will bring to the Gilead fold two tech platforms that can be applied to cell therapy and early stage treatments for prostate cancer and a type of blood cancer.
By Dana Bartholomew
Source: LA Business Journal
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
